September 17, 2021
EXKIVITY (mobocertinib) approved and Takeda has selected Onco360® as a Specialty Pharmacy Partner
August 18, 2021
Onco360® has been selected by Merck & Co., Inc. to be in the specialty pharmacy network for WELIREG (belzutifan) ), a hypoxia-inducible factor inhibitor indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.
July 22, 2021
REZUROCKTM (belumosudil) tablets approved to treat adult and pediatric patients 12 years and older with chronic graft-versus-host disease after failure of at least two prior lines of therapy
June 4, 2021
LUMAKRAS (Sotorasib) Now Approved for the Treatment of Adult Patients with KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
June 1, 2021
ALUNBRIG® (brigatinib) Approved for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)-positive Metastatic Non-Small Cell Lung Cancer (NSCLC)
March 15, 2021
Onco360® Selected as Specialty Pharmacy Partner for FOTIVDA® (tivozanib)
February 8, 2021
UKONIQ™ (umbralisib) Now Approved by the FDA; Onco360® Selected as Exclusive Specialty Pharmacy Partner
December 17, 2020
Onco360® to provide 50,000 meals to children and families through Feeding America's network of food banks.
June 22, 2020
TAZVERIK™ (tazemetostat) is now approved for the treatment of relapsed/refractory follicular lymphoma, available from Onco360.
May 13, 2020
Onco360® has been selected by Eli Lilly to be a specialty pharmacy partner for RETEVMO™ (selpercatinib), a novel oral treatment for adult patients with (RET) fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC) and metastatic RET fusion-positive thyroid cancer.